• Login
    View Item 
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2018 RD&E publications
    • View Item
    •   RD&E Research Repository Home
    • All RD&E publications by year
    • 2018 RD&E publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease.

    Thumbnail
    View/Open
    Open Access article (295.6Kb)
    URI
    http://hdl.handle.net/11287/620607
    Author
    Halpin, David M
    Date
    2018-01
    Journal
    Tuberculosis and respiratory diseases
    Type
    Journal Article
    Publisher
    Tuberculosis & Respiratory Diseases
    DOI
    10.4046/trd.2017.0098
    Rights
    Archived with thanks to Tuberculosis and respiratory diseases. Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).
    Metadata
    Show full item record
    Abstract
    Bronchodilator therapy is central to the management of chronic obstructive pulmonary disease and are recommended as the preferred treatment by the Global Obstructive Lung Disease Initiative (GOLD). Long acting anti-muscarinics (LAMA) and long acting β₂ agonists (LABA) are both more effective than regular short-acting drugs but many patients remain symptomatic despite monotherapy with these drugs. Combination therapy with LAMA and LABA increases the therapeutic benefit while minimizing dose-dependent side effects of long-acting bronchodilator therapy. The TOviTO programme has investigated the benefits of treatment with a combination of tiotropium and olodaterol administered via a single inhaler. Tiotropium+olodaterol 5/5 μg significantly improved forced expiratory volume in 1 second (FEV₁) area under the curve from 0 to 3 hours, trough FEV₁ health status and breathlessness versus the mono-components and placebo. Tiotropium+olodaterol 5/5 μg also increased endurance time and reduced dynamic hyperinflation during constant work rate cycle ergometry. On the basis of these and other studies the 2017 GOLD report recommends escalating to dual bronchodilator therapy in patients in groups B and C if they remain symptomatic or continue to have exacerbations and as initial therapy for patients in group D.
    Citation
    The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease. 2018, 81 (1):13-18 Tuberc Respir Dis (Seoul)
    Publisher URL
    https://www.e-trd.org/DOIx.php?id=10.4046/trd.2017.0098
    Note
    This article is freely available via Open Access. Click on the Additional Link above to access the full-text via the publisher's site.
    Collections
    • 2018 RD&E publications
    • Respiratory

    Browse

    All of RD&E Research RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2023  DuraSpace
    Contact Us | Send Feedback
    DSpace Express is a service operated by 
    Atmire NV